Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Lindskog

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
European Urology Open Science|May 9, 2022
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register StudyTarik Almdalal, Pernilla Sundqvist, Ulrika Harmenberg, et al.
Journal of Natural Products|November 10, 2009
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugsJenny Felth, Linda Rickardson, Josefin Rosén, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 6, 2009
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediatesHelena Gleissman, Rong Yang, Kimberly Martinod, et al.
Cancer Letters|June 25, 2005
NSAIDs in neuroblastoma therapyJohn I Johnsen, Magnus Lindskog, Frida Ponthan, et al.
Cancer Research|October 20, 2004
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivoJohn I Johnsen, Magnus Lindskog, Frida Ponthan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2012
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapySverre Sörenson, Helena Fohlin, Andrea Lindgren, et al.
International Journal of Cancer|December 6, 2008
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivoEbba Palmberg, John Inge Johnsen, Janna Paulsson, et al.
BMC Pharmacology & Toxicology|March 5, 2024
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessmentTove Selvin, Malin Berglund, Lena Lenhammar, et al.
Cancer Management and Research|February 26, 2019
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysisJosefine Redig, Johan Dalén, Ulrika Harmenberg, et al.
Cancer Letters|June 11, 2005
Proton magnetic resonance spectroscopy in neuroblastoma: current status, prospects and limitationsMagnus Lindskog, Christian Spenger, Tomas Klason, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
European Urology Open Science|May 9, 2022
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register StudyTarik Almdalal, Pernilla Sundqvist, Ulrika Harmenberg, et al.
Journal of Natural Products|November 10, 2009
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugsJenny Felth, Linda Rickardson, Josefin Rosén, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 6, 2009
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediatesHelena Gleissman, Rong Yang, Kimberly Martinod, et al.
Cancer Letters|June 25, 2005
NSAIDs in neuroblastoma therapyJohn I Johnsen, Magnus Lindskog, Frida Ponthan, et al.
Cancer Research|October 20, 2004
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivoJohn I Johnsen, Magnus Lindskog, Frida Ponthan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2012
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapySverre Sörenson, Helena Fohlin, Andrea Lindgren, et al.
International Journal of Cancer|December 6, 2008
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivoEbba Palmberg, John Inge Johnsen, Janna Paulsson, et al.
BMC Pharmacology & Toxicology|March 5, 2024
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessmentTove Selvin, Malin Berglund, Lena Lenhammar, et al.
Cancer Management and Research|February 26, 2019
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysisJosefine Redig, Johan Dalén, Ulrika Harmenberg, et al.
Cancer Letters|June 11, 2005
Proton magnetic resonance spectroscopy in neuroblastoma: current status, prospects and limitationsMagnus Lindskog, Christian Spenger, Tomas Klason, et al.
Pageof 5